key: cord-0772287-j87jk21e authors: Calza, Leonardo; Bon, Isabella; Borderi, Marco; Colangeli, Vincenzo; Borioni, Aurora; Re, Maria Carla; Viale, Pierluigi title: COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection date: 2021-01-01 journal: J Acquir Immune Defic Syndr DOI: 10.1097/qai.0000000000002537 sha: 67a6070aee09f0047b3d14be48f99b340615891a doc_id: 772287 cord_uid: j87jk21e nan To the Editors: In December 2019, an interstitial pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city, China. This viral disease, which has subsequently been named coronavirus disease 2019 , became in the following weeks a disastrous global pandemic, with more than 12 million confirmed cases and 500,000 deaths worldwide on July 15, 2020. [1] [2] [3] Clinical studies suggest advanced age and chronic comorbidities (mostly hypertension, diabetes mellitus, and obesity) are associated with worse outcomes of SARS-CoV-2 infection, but it is not clear to date if human immune deficiency virus-1 (HIV-1) infection is a risk factor for greater severity and higher mortality of COVID-19. 4, 5 In some cohort studies, HIVinfected persons hospitalized for COVID-19 had similar clinical characteristics and outcomes with other hospitalized cohorts of HIVuninfected patients, and risk of COVID-19 and severe disease in suppressed HIV-positive people seems to be comparable with the general population. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Particularly, a recent systematic review suggests that patients with controlled HIV infection (or rather with CD4 + lymphocyte count .200 cells/mm 3 and undetectable viral load) have the same risk of contracting SARS-CoV-2 infection or experiencing more severe COVID-19 in comparison with HIV-uninfected people. 17 However, very limited evidence is available still today about the clinical course and outcomes of COVID-19 in HIV-positive persons with poor immunological status and detectable HIV RNA. So, we have performed a retrospective analysis of patients with uncontrolled HIV infection and COVID-19 diagnosed in our clinics. Uncontrolled HIV infection was defined by current CD4 + lymphocyte count ,350 cells/mm 3 and HIV RNA $50 copies/mL. Diagnosis of COVID-19 was made by detection of SARS-CoV-2 RNA in oropharyngeal and/or nasopharyngeal swab specimens by realtime RT-PCR targeting regions in the N gene, following the US CDC protocol. Between March 1, 2020, and June 30, 2020, a total of 31 coinfections with HIV-1 and SARS-CoV-2 were diagnosed at the S.Orsola Hospital in Bologna (Emilia-Romagna region, Italy). Among these cases, 9 patients (29%) had an uncontrolled HIV infection. Characteristics, treatments, and outcomes of these patients are summarized in Table 1 . All patients gave informed consent. Overall, 7 (78%) were men, the median age was 56.2 years (range, 41-73), and all were currently treated with combination antiretroviral therapy (cART). Six subjects had CD4 + lymphocyte count ranging between 200 and 350 cells/mm 3 , and 3 subjects had CD4 + lymphocyte count ,200 cells/mm 3 . Four patients had a previous diagnosis of an AIDS-defining condition: Pneumocystis jirovecii pneumonia in 3 cases, and Kaposi's sarcoma in 1 case. Plasma HIV RNA ranged between 66 and 1240 copies/mL, and 7 patients had HIV RNA ,200 copies/mL. Current cART included 1boosted protease inhibitor (PI) in 3 cases, 1 integrase strand transfer inhibitor in 4, and 1 nonnucleoside reverse transcriptase inhibitor in 2. Seven patients had one or more comorbidities, and 3 patients had 2 comorbidities. Clinical diagnosis was represented by upper respiratory tract infection in 7 cases and interstitial pneumonia in 2. At diagnosis, the median duration of symptoms was 3.6 days, and most frequent symptoms were fever .38°C, cough, fatigue, and myalgia. Only 1 subject had an initial respiratory failure with a PaO 2 / FiO 2 ratio ,300 at arterial blood gas analysis. Overall, 3 patients (33%) were hospitalized, whereas other 6 subjects had mild symptoms and spent their disease period at home. At diagnosis, 3 patients were receiving a PI-based cART, including darunavir-cobicistat in all cases. A transitional change in cART was made in other 2 patients who were treated with a non-boosted PIbased regimen, because of the potential activity of HIV PIs against the coronavirus protease. 18 So, darunavir/cobicistat replaced rilpivirine in 1 case and efavirenz in 1 case. Regarding other drug treatments, we prescribed hydroxychloroquine in 5 subjects and enoxaparin in 3, whereas tocilizumab and corticosteroids were not used. A clinical recovery was obtained in all patients, whereas there were no admissions to the ICU and no deaths. The 3 hospitalized patients were discharged after a median of 8.5 days, and the median global duration of symptoms before recovery in all observed patients was 9.2 days. The median duration of positivity for SARS-CoV-2 RNA in oropharyngeal and/or nasopharyngeal swab was 16.2 days, and all patients tested negative at oro and/or nasopharyngeal swab 21 days after the onset of symptoms. The clinical course and outcome of COVID-19 among patients with uncontrolled HIV infection are still unknown, and so far, only few cases of COVID-19 in subjects with poor immunological status or AIDS have been described in case series. 17 One patient with AIDS reported by Blanco et al 8 was admitted to the ICU and required noninvasive ventilation but responded well to drug therapy and was discharged after 12 days. Guo et al 19 described 1 patient with AIDS who tested positive for SARS-CoV-2 but had an asymptomatic infection with a normal chest CT scan. A patient with very low CD4 + lymphocyte count (34 cells/mm 3 ) who experienced an interstitial pneumonia with a very long disease course (2 months) and delayed immune response was presented by Wang et al. 20 Harter et al 10 described 4 patients with low CD4 + lymphocyte count: 1 patient with 69 CD4 + lymphocytes/mm 3 had severe interstitial pneumonia and died, whereas 3 subjects had mild infections and recovered. So, outcomes of COVID-19 in HIV-infected patients with low CD4 + cell count ranged from asymptomatic infec-tion to severe disease and death, and conclusions cannot be drawn on the severity of COVID-19 in AIDS patients. In our experience, COVID-19 in patients with uncontrolled HIV infection was frequently associated with chronic comorbidities and had a clinical presentation comparable with that of both patients with controlled HIV infection and HIV-negative population. No patients were admitted to the ICU or required mechanical ventilation, and all subjects recovered after a median of 9 days. Therefore, in our report, uncontrolled HIV infection did not seem to be associated with greater severity and worse outcome of SARS-CoV-2 infection. Obviously, our study is limited by the retrospective design and the very limited number of patients; so, larger cohort studies are needed to better understand the real effect of HIV infection on COVID-19. Clinical features of patients infected with 2019 novel coronavirus in Wuhan A novel coronavirus from patients with pneumonia in China COVID-19 cases update Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics SARS-CoV-2 and HIV Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city COVID-19 in patients with HIV: clinical case series Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients Clinical characteristics and outcomes in people living with HIV hospitalized for COVID-19 COVID-19 pneumonia in patients with HIVa case series COVID-19 in 3 people living with HIV in the United Kingdom Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States co-infection: a retrospective, record based, case series from South India Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 Quick community survey on the impact of COVID-19 outbreak for the healthcare of people living with HIV One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4 + T-cell count